World's Best Scientists 2026 revealed!
Keith T. Flaherty

Keith T. Flaherty

D-Index & Metrics

Medicine

D-Index
156
Citations
136827
World Ranking
897
National Ranking
512

Overview

Keith T. Flaherty is affiliated with Harvard University in the United States and has contributed extensively to research in medicine and biochemistry, genetics, and molecular biology. Their work spans several subfields, with a strong focus on oncology, molecular biology, cancer research, pulmonary and respiratory medicine, and immunology.

Their main research topics include:

  • Melanoma and MAPK Pathways
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Colorectal Cancer Treatments and Studies
  • Immunotherapy and Immune Responses

Keith T. Flaherty has published extensively in high-impact scientific journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • JCO Precision Oncology

Some of their recent papers are:

  • "SARS-CoV-2 viral load is associated with increased disease severity and mortality" (2020, Nature Communications)
  • "Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity" (2020, Science)
  • "Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)" (2020, Journal of Clinical Oncology)
  • "Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H" (2020, Journal of Clinical Oncology)
  • "The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design" (2020, JNCI Journal of the National Cancer Institute)

Keith T. Flaherty has collaborated with several frequent co-authors including:

  • Genevieve M. Boland
  • Lyndsay N. Harris
  • Lisa M. McShane
  • Ryan J. Sullivan
  • Stanley R. Hamilton

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    Itay Tirosh;Benjamin Izar;Benjamin Izar;Sanjay M. Prakadan;Marc H. Wadsworth

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

    Ravid Straussman;Teppei Morikawa;Kevin Shee;Michal Barzily-Rokni

  • Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

    Leore T. Geller;Michal Barzily-Rokni;Tal Danino;Oliver H. Jonas;Oliver H. Jonas

  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

    Cory M Johannessen;Jesse S. Boehm;So Young Kim;Sapana R. Thomas;Sapana R. Thomas

  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Poulikos I. Poulikakos;Yogindra Persaud;Manickam Janakiraman;Xiangju Kong

  • Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

    Moshe Sade-Feldman;Moshe Sade-Feldman;Keren Yizhak;Stacey L. Bjorgaard;Stacey L. Bjorgaard;John P. Ray

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    I. Tirosh;B. Izar;D. Treacy;J. J. Trombetta

Frequent Co-Authors

Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Dennie T. Frederick
Dennie T. Frederick Broad Institute
Georgina V. Long
Georgina V. Long University of Sydney
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Reinhard Dummer
Reinhard Dummer University of Zurich
Claus Garbe
Claus Garbe University of Tübingen
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medicine but prefer flexible study options? There are several accredited online degrees that can launch your career in healthcare without the need for traditional, on-campus programs.

Many students are choosing a health information technology online degree to enter the growing field of medical records management. This pathway offers job stability and the opportunity to work in both clinical and non-clinical settings.

Those looking for fast entry into the workforce may consider a medical billing and coding certification online. These programs are designed to be completed in less time and train students in essential skills for administrative roles in healthcare.

Aspiring nurses can save on tuition with affordable nursing programs online or pursue advanced practice through the cheapest online fnp program. Both tracks offer flexibility for working professionals and help address the national demand for skilled nurses.

Each online pathway provides an accessible, affordable alternative to traditional degrees, opening more opportunities in America’s dynamic healthcare sector.

Best Scientists Citing Keith T. Flaherty

Trending Scientists

Recently Published Articles